
RAPP Stock Forecast & Price Target
RAPP Analyst Ratings
Bulls say
Rapport Therapeutics Inc has seen notable momentum in its stock performance following its inaugural R&D Day and the positive Phase 2a data released on September 8. The data from the Phase 2a trial, involving 30 patients with refractory focal onset epilepsy, indicates a significantly improved therapeutic window for their candidate drug, RAP-219, supported by earlier preclinical and Phase 1 studies. The rapid and substantial control of seizures demonstrated by RAP-219 suggests a strong potential for success in upcoming Phase 3 trials, indicating a commercially competitive profile even with a conservative estimate of efficacy.
Bears say
Rapport Therapeutics Inc faces a challenging outlook due to concerns regarding the efficacy estimates from its Phase 2a trial, where the exclusion of patients from the analysis raises doubts about the robustness of these results and may lead to lower efficacy in Phase 3 trials. Furthermore, even with potential regulatory approval, the company's market position could be adversely affected by significant competition and unfavorable insurance coverage, limiting the commercial viability of its drugs. These factors contribute to apprehensions about the company's financial future and overall stock performance.
This aggregate rating is based on analysts' research of Rapport Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
RAPP Analyst Forecast & Price Prediction
Start investing in RAPP
Order type
Buy in
Order amount
Est. shares
0 shares